
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd is a biopharmaceutical company with a strong focus on developing monoclonal antibodies for the prevention and treatment of serious viral infectious diseases. The company's lead product, PEMGARDA, has received emergency use authorization for the prevention of COVID-19 in immunocompromised individuals and has demonstrated a strong correlation between neutralizing antibodies and clinical protection. The company's pipeline also includes VYD2311 for COVID-19 and VBY329 for RSV infections, with plans to enter clinical development for these candidates in 2027. The company's focus on monoclonal antibodies positions them well for success in the growing market for alternative treatments to traditional vaccines and their strong management team inspires confidence in the potential success of their products.
Bears say
Invivyd is a biopharmaceutical company with one commercial product, PEMGARDA, facing potential reimbursement issues and its next-generation antibody candidates in early stages of development. The company's focus on monoclonal antibodies for viral diseases, while promising, may lead to limited market opportunities and high competition. With uncertain trial outcomes and the potential for safety concerns, the company's future success is highly speculative and may not justify its current valuation based on a discounted cash flow analysis.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares